SEC Filing Summary: Sunshine Heart, Inc. (Form 8-K)
Business Context and Reporting Period
Company: Sunshine Heart, Inc.
Filing Date: February 25, 2015
Reporting Period: Current Report (Event Date: February 25, 2015)
Business Context: The Company is a medical device developer focused on the C-Pulse system, a balloon counterpulsation treatment designed to improve heart function and reduce re-hospitalizations for patients with NYHA Class III and ambulatory Class IV heart failure.
Key Financial Metrics
This filing is a Current Report on Form 8-K regarding a regulatory milestone and does not contain financial statements. The filing text does not provide values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
Regulatory Approval: On February 25, 2015, the Company received unconditional approval from the U.S. Food and Drug Administration (FDA) to conduct an interim analysis of its U.S. pivotal study, known as COUNTER HF.
- Study Details: COUNTER HF is a prospective, randomized, multi-center, controlled study.
- Objective: To evaluate the safety and efficacy of the C-Pulse system.
- Target Population: Patients with NYHA Class III and ambulatory Class IV heart failure.
Guidance, Outlook, and Risks
Management Commentary: The interim analysis is integral to the COUNTER HF study, which assesses the unique balloon counterpulsation treatment. The approval allows the Company to proceed with this critical evaluation phase.
Risks and Contingencies: The filing notes that the information is furnished pursuant to Item 7.01 (Regulation FD Disclosure) and is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934. No specific financial risks or contingencies are detailed in this document.
Investor Verification Checklist
- Verify the specific criteria and timeline for the FDA-approved interim analysis of the COUNTER HF study.
- Review the attached press release (Exhibit 99.1) for detailed commentary on the study design and expected outcomes.
- Monitor future filings for the results of the interim analysis and any subsequent impact on the Company's regulatory pathway or financial position.
- Confirm the Company's current cash runway and funding status, as this filing does not disclose liquidity metrics.